Archives

Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes

B – 13-week U.S. Phase II study is evaluating the efficacy, safety and tolerability of oral small molecule GLP-1R agonist ASC30, a once-daily tablet, in… Login to continue reading Login…

Read MoreAscletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes

Apollo Global Deadline: APO Investors Have Opportunity to Lead Apollo Global Management, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

B NEW YORK, April 26, 2026 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Apollo Global Management,… Login to continue reading Login…

Read MoreApollo Global Deadline: APO Investors Have Opportunity to Lead Apollo Global Management, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

Power Solutions International, Inc. Investors Have Opportunity to Lead Power Solutions International, Inc. Securities Fraud Lawsuit

B NEW YORK, April 26, 2026 /PRNewswire/ —  Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Power Solutions… Login to continue reading Login…

Read MorePower Solutions International, Inc. Investors Have Opportunity to Lead Power Solutions International, Inc. Securities Fraud Lawsuit